country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-P992158

Copy Link Print Information

VBI-009

VBI-009 is a CD47 and B7-H3 (CD276) bispecific antibody. VBI-009 blocks CD47-SIRPα 'don't eat me' signals and restricts activity to CD47⁺/B7-H3⁺ cells. VBI-009 induces antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) in CD47⁺/B7-H3⁺ tumor cells. VBI-009 inhibits tumor growth in CD47+/B7-H3+ lung cancer xenograft models. VBI-009 can be used for the research of lung cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

VBI-009 構造式

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Species Reactivity
- 体外実験
- 体内実験
- 遺伝子ID
- アクセッション番号
- Target
- Conjugated
- Reconsititution
- Format
- アプリケーション
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Species Reactivity

Human

体外実験

VBI-009 selectively binds to CD47⁺/B7-H3⁺ tumor cells, shows minimal to no binding to B7-H3-negative cells, and does not bind significantly to human red blood cells^[1].
VBI-009 potently blocks the CD47/SIRPα axis on CD47⁺/B7-H3⁺ tumor cells, with minimal to no activity on B7-H3-negative cells^[1].
VBI-009 drives potent antibody-dependent cellular phagocytosis of CD47⁺/B7-H3⁺ tumor cells, with minimal to no activity on B7-H3-negative cells^[1].
VBI-009 drives potent antibody-dependent cellular cytotoxicity of CD47⁺/B7-H3⁺ tumor cells, with minimal to no activity on B7-H3-negative cells^[1].
VBI-009 does not induce hemagglutination of human red blood cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

BI-009 inhibits tumor growth in CD47⁺/B7-H3₊ lung cancer xenograft models^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

遺伝子ID

80381 [NCBI] & 16423 [NCBI]

アクセッション番号

Q5ZPR3 & Q61735-1

Target

B7-H3/CD276 & CD47

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Product Image

アプリケーション

ELISA, FACS, Functional assay

化学情報

Formulation

Please refer to the lot-specific COA for specific buffer information.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

Inhibitory Antibodies User Guide (603 KB)

参考文献

[1]. Wang X, et al. 516 CD47 x B7-H3 bispecific antibody offers a new strategy for treating B7-H3+/CD47+ tumors[J]. 2023.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ